Cybin provides update on its intellectual property portfolio

Toronto--(business wire)--cybin inc. (neo:cybn) (nyse american:cybn) (“cybin” or the “company”), a biopharmaceutical company focused on progressing psychedelics to therapeutics®, is pleased to provide an update on its intellectual property (“ip”) progress in support of its research and development strategy. the company continues to prioritize the development of in-house ip and licensing opportunities that support its active development programs and future novel drug candidates. cybin currently
CYBN Ratings Summary
CYBN Quant Ranking